$12 million for Univercells's vaccines

January 3, 2017 News BioVox

The Gosselies-based Univercells received a $12 million grant from the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing platform. The objective is to radically lower costs and increase vaccine availability and affordability in developing countries. The development will be performed by a consortium, including Batavia Biosciences and Natrix Separations.

Hugues Bultot, CEO and co-founder of Univercells says: “We are extremely honored to partner with the Gates Foundation to significantly increase global access to priority vaccines by lowering their manufacturing cost”.

The consortium will focus on developing  a manufacturing platform that integrates continuous processing with extremely high process intensification. This combination will allow miniaturization of commercial manufacturing to the point where it can be performed in local, low-cost micro-facilities.  The first target is to create a polio vaccine facility, that produces 40 million doses per year,  costing only 0.15$ per dose.

José Castillo, CTO and co-founder of Univercells, stated: “We are excited about this partnership with the Bill & Melinda Gates Foundation. With Batavia Bioscience and Natrix Separations, our consortium integrates considerable experience, know-how and innovative but proven technologies that tremendously increase manufacturing productivity. As a result, we expect our integrated platform to be a real game-changer for global health.”

You might also be interested in “Bill & Melinda Gates Foundation Fund University of Antwerp’s Polio Research”

Read more about the Bill & Melinda Gates Foundation


Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter